JP2003510359A - 化合物および方法 - Google Patents

化合物および方法

Info

Publication number
JP2003510359A
JP2003510359A JP2001527795A JP2001527795A JP2003510359A JP 2003510359 A JP2003510359 A JP 2003510359A JP 2001527795 A JP2001527795 A JP 2001527795A JP 2001527795 A JP2001527795 A JP 2001527795A JP 2003510359 A JP2003510359 A JP 2003510359A
Authority
JP
Japan
Prior art keywords
anilino
triazole
methyl
benzylthio
ylthio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001527795A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003510359A5 (OSRAM
Inventor
ジョゼフ・ピー・マリーノ・ジュニア
スコット・ケイ・トンプソン
ダニエル・フランク・ベーバー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JP2003510359A publication Critical patent/JP2003510359A/ja
Publication of JP2003510359A5 publication Critical patent/JP2003510359A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2001527795A 1999-10-01 2000-09-29 化合物および方法 Pending JP2003510359A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15728699P 1999-10-01 1999-10-01
US60/157,286 1999-10-01
PCT/US2000/026951 WO2001024796A1 (en) 1999-10-01 2000-09-29 1,2,4-triazole derivatives, composition, process of making and methods of use

Publications (2)

Publication Number Publication Date
JP2003510359A true JP2003510359A (ja) 2003-03-18
JP2003510359A5 JP2003510359A5 (OSRAM) 2007-11-22

Family

ID=22563095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001527795A Pending JP2003510359A (ja) 1999-10-01 2000-09-29 化合物および方法

Country Status (5)

Country Link
US (1) US7304082B2 (OSRAM)
EP (1) EP1223932A4 (OSRAM)
JP (1) JP2003510359A (OSRAM)
AU (1) AU7989400A (OSRAM)
WO (1) WO2001024796A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503009A (ja) * 2002-08-09 2006-01-26 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体−５の調節因子としての１，２，４−オキサジアゾール類
JP2013532660A (ja) * 2010-07-22 2013-08-19 ザフゲン，インコーポレイテッド 三環式化合物ならびにその作製および使用方法
JP2017517546A (ja) * 2014-06-12 2017-06-29 ユニヴェルシテ・ドゥ・リール・２・ドロワ・エ・サンテ イミダゾール−または１，２，４−トリアゾール−誘導体及びその使用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078697A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
JP2006504627A (ja) * 2002-03-27 2006-02-09 スミスクライン・ビーチャム・コーポレイション 化合物および方法
FR2862060A1 (fr) * 2003-11-06 2005-05-13 Galderma Res & Dev Procede de synthese en phase solide de composes de types sulfures de diaryle.
US8063083B2 (en) * 2006-05-25 2011-11-22 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
WO2011088055A2 (en) 2010-01-12 2011-07-21 Zafgen Corporation Methods and compositions for treating cardiovascular disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
CN103764652B (zh) 2011-05-06 2016-03-23 扎夫根股份有限公司 三环吡唑磺酰胺化合物及其制备和使用方法
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
US20140286902A1 (en) 2011-11-02 2014-09-25 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CA2861381A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
CA2861390A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
MX2014013599A (es) 2012-05-08 2015-05-11 Zafgen Inc Tratamiento de la obesidad hipotalamica con inhibidores de metap2.
US9573918B2 (en) 2012-05-09 2017-02-21 Zafgen, Inc. Fumigillol compounds and methods of making and using same
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
MX2015005732A (es) 2012-11-05 2015-12-16 Zafgen Inc Compuestos tricíclicos y métodos para hacer y utilizar los mismos.
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
BR112015023390A2 (pt) 2013-03-14 2017-07-18 Zafgen Inc métodos para tratar de doença renal e outros distúrbios
WO2015089800A1 (en) 2013-12-19 2015-06-25 Eli Lilly And Company Fluorophenyl pyrazol compounds
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
MA52489A (fr) * 2018-05-04 2021-03-10 Inflazome Ltd Nouveaux composés

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55120571A (en) * 1979-03-02 1980-09-17 Glaxo Group Ltd Heterocyclic derivative
JPS5993063A (ja) * 1982-09-01 1984-05-29 ビオガル・ジヨジツエルジヤ−ル アシル化１，２，４−トリアゾ−ル誘導体およびその製造方法
JPS6452763A (en) * 1980-02-28 1989-02-28 Glaxo Group Ltd Novel heterocyclic derivative, manufacture and medicinal composition
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
US5883110A (en) * 1995-06-07 1999-03-16 Sugen, Inc. Pharmaceutical compositions and methods for modulating signal transduction
JP2002544178A (ja) * 1999-05-07 2002-12-24 ビーエーエスエフ アクチェンゲゼルシャフト 腎機能障害の治療用の医薬の製造のためのドーパミン−ｄ３−レセプターリガンドの使用
JP2003502286A (ja) * 1999-05-11 2003-01-21 ビーエーエスエフ アクチェンゲゼルシャフト フタラジン誘導体の使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760448A (en) * 1987-05-04 1988-07-26 Sencore, Inc. Method of measuring amplitude variations of a video carrier and apparatus therefor
JPH01160972A (ja) * 1987-12-18 1989-06-23 Tsumura & Co １，２，４−トリアゾール誘導体及びそれを有効成分として含有する抗潰瘍剤
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9207396D0 (en) 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
DE4424787A1 (de) 1994-07-14 1996-01-18 Bayer Ag Substituierte Aryliminoheterocyclen
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
CN1166835A (zh) * 1994-11-29 1997-12-03 隆萨股份公司 光学活性金属茂基膦的制备方法
US20020168761A1 (en) * 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
WO2001036404A1 (en) 1999-11-19 2001-05-25 Smithkline Beecham Corporation Compounds and methods
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
AU2001253418A1 (en) * 2000-04-12 2001-10-30 Smith Kline Beecham Corporation Compounds and methods
WO2002005804A1 (en) 2000-07-19 2002-01-24 Smithkline Beecham Corporation Compounds and methods
JP2004525942A (ja) * 2001-03-29 2004-08-26 スミスクライン・ビーチャム・コーポレイション 化合物および方法
JP2005506299A (ja) * 2001-03-29 2005-03-03 スミスクライン・ビーチャム・コーポレイション 化合物および方法
JP2004535377A (ja) 2001-04-03 2004-11-25 スミスクライン・ビーチャム・コーポレイション Ｍｅｔａｐ２を阻害する方法
US20040192914A1 (en) * 2001-10-12 2004-09-30 Kallander Lara S Compounds and methods
WO2003051906A2 (en) 2001-12-14 2003-06-26 Smithkline Beecham Corporation Compounds and methods
JP2003281388A (ja) * 2002-03-25 2003-10-03 Hitachi Ltd 自動取引装置
JP2006504627A (ja) * 2002-03-27 2006-02-09 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US20040116490A1 (en) * 2002-03-28 2004-06-17 Marino Jr. Joseph P. Compounds and methods

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55120571A (en) * 1979-03-02 1980-09-17 Glaxo Group Ltd Heterocyclic derivative
JPS6452763A (en) * 1980-02-28 1989-02-28 Glaxo Group Ltd Novel heterocyclic derivative, manufacture and medicinal composition
JPS5993063A (ja) * 1982-09-01 1984-05-29 ビオガル・ジヨジツエルジヤ−ル アシル化１，２，４−トリアゾ−ル誘導体およびその製造方法
US5883110A (en) * 1995-06-07 1999-03-16 Sugen, Inc. Pharmaceutical compositions and methods for modulating signal transduction
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
JP2002544178A (ja) * 1999-05-07 2002-12-24 ビーエーエスエフ アクチェンゲゼルシャフト 腎機能障害の治療用の医薬の製造のためのドーパミン−ｄ３−レセプターリガンドの使用
JP2003502286A (ja) * 1999-05-11 2003-01-21 ビーエーエスエフ アクチェンゲゼルシャフト フタラジン誘導体の使用

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503009A (ja) * 2002-08-09 2006-01-26 アストラゼネカ アクチボラグ 代謝調節型グルタミン酸受容体−５の調節因子としての１，２，４−オキサジアゾール類
JP2010248214A (ja) * 2002-08-09 2010-11-04 Astrazeneca Ab 代謝調節型グルタミン酸受容体−５の調節因子としての１，２，４−オキサジアゾール類
JP2013532660A (ja) * 2010-07-22 2013-08-19 ザフゲン，インコーポレイテッド 三環式化合物ならびにその作製および使用方法
JP2017517546A (ja) * 2014-06-12 2017-06-29 ユニヴェルシテ・ドゥ・リール・２・ドロワ・エ・サンテ イミダゾール−または１，２，４−トリアゾール−誘導体及びその使用

Also Published As

Publication number Publication date
AU7989400A (en) 2001-05-10
US7304082B2 (en) 2007-12-04
EP1223932A4 (en) 2003-01-15
WO2001024796A8 (en) 2001-05-17
WO2001024796A1 (en) 2001-04-12
US20050267185A1 (en) 2005-12-01
EP1223932A1 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
JP2003510359A (ja) 化合物および方法
US20030220371A1 (en) Compounds and methods
TWI226329B (en) Compounds of the formula I for the treatment of ischemia, and pharmaceutical composition comprising the same
JP2004525942A (ja) 化合物および方法
JP5775452B2 (ja) 肝細胞増殖因子（分散因子）活性の低分子モジュレーターの組成物および方法
CZ20031941A3 (cs) Substituované triazol diaminové deriváty jako inhibitory kináz
CN1747730B (zh) 肝细胞生长因子(分散因子)活性的吡唑衍生物调节剂
MXPA01012903A (es) Compuestos de 5-aril-1h-1, 2, 4-triazola como inhibidores de ciclooxigenasa-2 y composiciones farmaceuticas que los contienen.
JP2010248205A (ja) 強皮症の治療のためのベンザゾール誘導体
US20040192914A1 (en) Compounds and methods
WO2003051906A2 (en) Compounds and methods
US20060247280A1 (en) Compounds and methods
US20040116490A1 (en) Compounds and methods
JP2014509297A (ja) 肝細胞増殖因子（散乱因子）活性の小分子モジュレーターの使用方法
US6486158B1 (en) [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
JP2005508841A (ja) 化合物および方法
US20050222212A1 (en) Compounds and methods
CN117940166A (zh) 用于治疗疼痛的sos1抑制剂和ras抑制剂
WO2001036404A1 (en) Compounds and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110329